Atea Pharmaceuticals Revenue

AVIR -  USA Stock  

USD 12.73  0.02  0.16%

Atea Pharmaceuticals fundamentals help investors to digest information that contributes to Atea Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Atea Pharmaceuticals Stock. This fundamental analysis module provides a way for investors to measures Atea Pharmaceuticals' intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atea Pharmaceuticals stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Atea Pharmaceuticals Revenue 

 
Refresh
As of 10/23/2021, Revenue to Assets is likely to grow to 0.26, while Deferred Revenue is likely to drop slightly above 269.6 M.

Atea Pharmaceuticals Revenue Analysis

Atea Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
 2015 2016 2020 2021 (projected)
PPandE Turnover37.135.649.342.93
Long Term Debt to Equity0.0064940.0053480.006150.007743
Revenue 
 = 
Money Received 
Discounts and Returns 
More About Revenue | All Equity Analysis

Current Atea Pharmaceuticals Revenue

    
  175.01 M  
Most of Atea Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atea Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Atea Pharmaceuticals Revenue Driver Correlations

Understanding the fundamental principles of building solid financial models for Atea Pharmaceuticals is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Revenue. Since Atea Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Atea Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Atea Pharmaceuticals' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Compare to competition
Based on the latest financial disclosure, Atea Pharmaceuticals reported 175.01 M of revenue. This is 97.71% lower than that of the sector and 76.44% lower than that of the Revenue industry. The revenue for all United States stocks is 98.15% higher than that of the company.

Atea Pharmaceuticals Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atea Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atea Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Atea Pharmaceuticals by comparing valuation metrics of similar companies.
Atea Pharmaceuticals is currently under evaluation in revenue category among related companies.

Atea Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Atea Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Atea Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Atea Pharmaceuticals' value.
Security TypeSharesValue
Frontier Capital Management Co Llc 1Common Shares179.3 K6.3 M
Axiom Investment Management LlcCommon Shares9.5 K336 K
Next Financial Group IncCommon Shares5.2 K183 K
Edge Wealth Management LlcCommon Shares50018 K
Ellevest IncCommon Shares7.00.0
Fmr LlcCommon Shares12.4 M266.6 M
Cormorant Asset Management LpCommon Shares6.4 M137.7 M

Atea Pharmaceuticals Fundamentals

About Atea Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Atea Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2021
Deferred Revenue271.2 M269.6 M
Revenues43.8 M43.5 M
Revenue to Assets 0.17  0.26 
Revenue Per EmployeeMM
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Bellus Health. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Atea Pharmaceuticals Piotroski F Score and Atea Pharmaceuticals Altman Z Score analysis. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.